We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
166 hedge funds and large institutions have $1.17B invested in Esperion Therapeutics in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 52 increasing their positions, 60 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
39% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $16.5M
2.05% less ownership
Funds ownership: 115.76% → 113.7% (-2.1%)
9% less funds holding
Funds holding: 182 → 166 (-16)
13% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 60
29% less capital invested
Capital invested by funds: $1.64B → $1.17B (-$474M)
41% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 27
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
166
Holders Change
-16
Holders Change %
-8.79%
% of All Funds
3.35%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
16
Increased
52
Reduced
60
Closed
27
Calls
$22.9M
Puts
$16.5M
Net Calls
+$6.44M
Net Calls Change
-$5.68M
Top Buyers
Top Sellers
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$28.7M |
| 2 |
Goldman Sachs
New York
|
-$10.6M |
| 3 |
Millennium Management
New York
|
-$10.4M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$7.97M |
| 5 |
Barclays
London,
United Kingdom
|
-$6.87M |
